<?xml version='1.0' encoding='utf-8'?>
<document id="30903758"><sentence text="The prevalence of potentially beneficial and harmful drug-drug interactions in intensive care units." /><sentence text="Background The present study was conducted with the aim of investigating the prevalence of potentially beneficial and harmful drug-drug interactions (DDIs) in intensive care units (ICUs)" /><sentence text=" Methods The present cross-sectional prospective study was conducted in two ICUs in Shahr-e Kord city, Iran" /><sentence text=" The study sample was consisted of 300 patients" /><sentence text=" The Drug Interaction Facts reference text book [Tatro DS" /><sentence text=" Drug interaction facts" /><sentence text=" St Louis, MO: Walters Kluwer Health, 2010" /><sentence text="] was used to determine the type and the frequency of the DDIs" /><sentence text=" Results The participants consisted of 189 patients men and 111 women" /><sentence text=" The mean age of patients was 44" /><sentence text="2 Â± 24" /><sentence text="6 years" /><sentence text=" Totally, 60" /><sentence text="5% of patients had at least one drug-drug interaction in their profile" /><sentence text=" The total number of DDIs found was 663 (the mean of the total number of drug-drug interactions was 2" /><sentence text="4 interactions per patient)" /><sentence text=" Of all the 663 interactions, 574 were harmful and others were beneficial" /><sentence text=" In terms of starting time, 98 of the potential interactions were rapid and 565 of them were delayed" /><sentence text=" In terms of severity, 511 of the potential interactions were moderate" /><sentence text=" Some of the drugs in the patients' medical records including phenytoin, dopamine, ranitidine, corticosteroid, dopamine, heparin, midazolam, aspirin, magnesium, calcium gluconate, and antibiotics, the type of ventilation, the type of nutrition and the duration of hospital stay were among the factors that were associated with high risk of potential DDIs (p &lt; 0"><entity charOffset="62-71" id="DDI-PubMed.30903758.s20.e0" text="phenytoin" /><entity charOffset="73-81" id="DDI-PubMed.30903758.s20.e1" text="dopamine" /><entity charOffset="83-93" id="DDI-PubMed.30903758.s20.e2" text="ranitidine" /><entity charOffset="95-109" id="DDI-PubMed.30903758.s20.e3" text="corticosteroid" /><entity charOffset="111-119" id="DDI-PubMed.30903758.s20.e4" text="dopamine" /><entity charOffset="130-139" id="DDI-PubMed.30903758.s20.e5" text="midazolam" /><entity charOffset="141-148" id="DDI-PubMed.30903758.s20.e6" text="aspirin" /><entity charOffset="150-159" id="DDI-PubMed.30903758.s20.e7" text="magnesium" /><entity charOffset="161-178" id="DDI-PubMed.30903758.s20.e8" text="calcium gluconate" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e0" e2="DDI-PubMed.30903758.s20.e0" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e0" e2="DDI-PubMed.30903758.s20.e1" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e0" e2="DDI-PubMed.30903758.s20.e2" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e0" e2="DDI-PubMed.30903758.s20.e3" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e0" e2="DDI-PubMed.30903758.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e0" e2="DDI-PubMed.30903758.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e0" e2="DDI-PubMed.30903758.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e0" e2="DDI-PubMed.30903758.s20.e7" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e0" e2="DDI-PubMed.30903758.s20.e8" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e1" e2="DDI-PubMed.30903758.s20.e1" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e1" e2="DDI-PubMed.30903758.s20.e2" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e1" e2="DDI-PubMed.30903758.s20.e3" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e1" e2="DDI-PubMed.30903758.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e1" e2="DDI-PubMed.30903758.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e1" e2="DDI-PubMed.30903758.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e1" e2="DDI-PubMed.30903758.s20.e7" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e1" e2="DDI-PubMed.30903758.s20.e8" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e2" e2="DDI-PubMed.30903758.s20.e2" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e2" e2="DDI-PubMed.30903758.s20.e3" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e2" e2="DDI-PubMed.30903758.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e2" e2="DDI-PubMed.30903758.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e2" e2="DDI-PubMed.30903758.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e2" e2="DDI-PubMed.30903758.s20.e7" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e2" e2="DDI-PubMed.30903758.s20.e8" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e3" e2="DDI-PubMed.30903758.s20.e3" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e3" e2="DDI-PubMed.30903758.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e3" e2="DDI-PubMed.30903758.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e3" e2="DDI-PubMed.30903758.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e3" e2="DDI-PubMed.30903758.s20.e7" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e3" e2="DDI-PubMed.30903758.s20.e8" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e4" e2="DDI-PubMed.30903758.s20.e4" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e4" e2="DDI-PubMed.30903758.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e4" e2="DDI-PubMed.30903758.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e4" e2="DDI-PubMed.30903758.s20.e7" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e4" e2="DDI-PubMed.30903758.s20.e8" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e5" e2="DDI-PubMed.30903758.s20.e5" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e5" e2="DDI-PubMed.30903758.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e5" e2="DDI-PubMed.30903758.s20.e7" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e5" e2="DDI-PubMed.30903758.s20.e8" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e6" e2="DDI-PubMed.30903758.s20.e6" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e6" e2="DDI-PubMed.30903758.s20.e7" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e6" e2="DDI-PubMed.30903758.s20.e8" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e7" e2="DDI-PubMed.30903758.s20.e7" /><pair ddi="false" e1="DDI-PubMed.30903758.s20.e7" e2="DDI-PubMed.30903758.s20.e8" /></sentence><sentence text="05)" /><sentence text=" Conclusions The prevalence of potentially beneficial and harmful DDIs, especially harmful drug-drug interactions, is high in ICUs and it is necessary to reduce these interactions by implementing appropriate programs and interventions" /><sentence text="" /></document>